Clinical Report: Ocular Risks of Glucagon-Like Peptide-1 Agonists
Overview
A new report highlights the ocular risks associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including worsening diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy. The report provides clinical recommendations for optometrists managing patients on these medications.
Background
The use of GLP-1 receptor agonists has increased significantly among adults for diabetes management and weight loss, with approximately 6% of adults using these medications as of 2024. Understanding the ocular risks associated with GLP-1 RAs is crucial for optometrists, as these drugs have been linked to serious eye conditions that can impact patient vision and quality of life. The recent report aims to guide optometric practice in monitoring and managing these risks effectively.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
- GLP-1 RAs have been associated with worsening diabetic retinopathy (DR) and nonarteritic anterior ischemic optic neuropathy (NAION).
- Patients starting GLP-1 RAs should undergo a comprehensive dilated eye examination within 12 months prior to or one month after starting therapy.
- NAION is considered a very rare adverse effect of semaglutide, prompting updates to product information by regulatory agencies.
- Recent studies indicate no increased risk of proliferative DR or treatment-requiring DR among new users of semaglutide compared to other agents.
- Clinical recommendations emphasize the need for tailored follow-up based on baseline disease severity in patients using GLP-1 RAs.
Clinical Implications
Optometrists should be vigilant in monitoring patients on GLP-1 RAs for potential ocular complications, particularly those with existing diabetic retinopathy or age-related macular degeneration. Implementing baseline dilated retinal exams and regular follow-ups can help mitigate risks and ensure timely intervention if ocular issues arise.
Conclusion
The report underscores the importance of awareness and proactive management of ocular risks associated with GLP-1 receptor agonists in clinical practice. By adhering to the recommended guidelines, optometrists can enhance patient care and outcomes.
References
- American Optometric Association, AOA, 2025 -- Glucagon-like Peptide-1 Receptor Agonists and Ocular Health
- Optometric Management, 2025 -- Diabetic Retinopathy and Glucagon-Like Peptide-1 Agonists
- Glaucoma Physician, 2025 -- The Impact of GLP-1 Receptor Agonists on Ocular Disease
- optometric management — What to Expect When You’re Expecting Ocular Complications From GLP-1 RAs
- glaucoma physician — The Impact of GLP-1 Receptor Agonists on Ocular Disease
- Clinical Report on GLP-1 RAs and Ocular Health
- GLP-1 Receptor Agonists and vision risk
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.